CD274 and non-small cell lung carcinoma: This hypothesis-generating meta-analysis showed that atezolizumab monotherapy was non-inferior to atezolizumab plus chemotherapy as a first-line treatment for patients with advanced NSCLC and PD-L1 TC3/IC3 expression.